HIGHLIGHTS
- who: Xuehua Xie from the Department of Medical Oncology, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, China have published the research: Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion, in the Journal: (JOURNAL) of April/29,/2014
SUMMARY
To seek personalized therapy strategies, paraffin-embedded sections of tumor tissues resected from the patient were subjected to real-time PCR (RT-PCR), and the results showed there were no EGFR mutations, MET amplifications or ALK fusions, but ROS1 fusion identified in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.